BACKGROUND: The survival benefit of heart transplantation in adult heart failure is greatest for the sickest patients and negligible for patients not requiring inotropic or mechanical support. We hypothesized a similar survival benefit of heart transplantation for childhood cardiomyopathies with heart failure. METHODS: A merged data set of children registered in both the Pediatric Cardiomyopathy Registry and the Pediatric Heart Transplant Study was used to assess differences in mortality before and after transplant in patients with different levels of heart failure severity. Severity was scored 2 if mechanical ventilatory or circulatory support was required, 1 if intravenous inotropes were required, or 0 if no support was required. RESULTS: For 332 eligible children, 12-month mortality after listing was 9% for those with a severity score of 0 (n = 105), 16% with a score of 1 (n = 118), and 26% with a score of 2 (n = 109; p = 0.002) with a 3%, 8%, and 20% mortality with severity scores at listing of 0, 1, and 2, respectively, occurring before transplant. Patients listed with a score of 0 frequently deteriorated: 50% received an allograft or died before transplant with severity scores of 1 or 2. The risk of deterioration increased with previous surgery (relative risk, 3.84; p = 0.03) in the short-term and with lower left ventricular mass z-score at time of presentation (relative risk, 1.74; p = 0.003) in the longer-term. CONCLUSION: Pediatric cardiomyopathy patients who require high levels of support receive a survival benefit from heart transplantation that is not shared by patients not requiring intravenous inotropic or mechanical support.
BACKGROUND: The survival benefit of heart transplantation in adult heart failure is greatest for the sickest patients and negligible for patients not requiring inotropic or mechanical support. We hypothesized a similar survival benefit of heart transplantation for childhood cardiomyopathies with heart failure. METHODS: A merged data set of children registered in both the Pediatric Cardiomyopathy Registry and the Pediatric Heart Transplant Study was used to assess differences in mortality before and after transplant in patients with different levels of heart failure severity. Severity was scored 2 if mechanical ventilatory or circulatory support was required, 1 if intravenous inotropes were required, or 0 if no support was required. RESULTS: For 332 eligible children, 12-month mortality after listing was 9% for those with a severity score of 0 (n = 105), 16% with a score of 1 (n = 118), and 26% with a score of 2 (n = 109; p = 0.002) with a 3%, 8%, and 20% mortality with severity scores at listing of 0, 1, and 2, respectively, occurring before transplant. Patients listed with a score of 0 frequently deteriorated: 50% received an allograft or died before transplant with severity scores of 1 or 2. The risk of deterioration increased with previous surgery (relative risk, 3.84; p = 0.03) in the short-term and with lower left ventricular mass z-score at time of presentation (relative risk, 1.74; p = 0.003) in the longer-term. CONCLUSION:Pediatric cardiomyopathypatients who require high levels of support receive a survival benefit from heart transplantation that is not shared by patients not requiring intravenous inotropic or mechanical support.
Authors: M A Grenier; S K Osganian; G F Cox; J A Towbin; S D Colan; P R Lurie; L A Sleeper; E J Orav; S E Lipshultz Journal: Am Heart J Date: 2000-02 Impact factor: 4.749
Authors: Daphne T Hsu; David C Naftel; Steven A Webber; William R Morrow; Charles E Canter; Richard E Chinnock; Mary Lynne Clark; James K Kirklin Journal: Congenit Heart Dis Date: 2006-05 Impact factor: 2.007
Authors: Richard Kirk; Leah B Edwards; Paul Aurora; David O Taylor; Jason D Christie; Fabienne Dobbels; Anna Y Kucheryavaya; Axel O Rahmel; Josef Stehlik; Marshall I Hertz Journal: J Heart Lung Transplant Date: 2009-10 Impact factor: 10.247
Authors: Jose N Nativi; Abdallah G Kfoury; Craig Myrick; Melissa Peters; Dale Renlund; Edward M Gilbert; Feras Bader; Arun K Singhal; Melanie Everitt; Patrick Fisher; David A Bull; Craig Selzman; Josef Stehlik Journal: J Heart Lung Transplant Date: 2009-09-26 Impact factor: 10.247
Authors: Charles E Canter; Robert E Shaddy; Daniel Bernstein; Daphne T Hsu; Maryanne R K Chrisant; James K Kirklin; Kirk R Kanter; Robert S D Higgins; Elizabeth D Blume; David N Rosenthal; Mark M Boucek; Karen C Uzark; Alan H Friedman; Allen H Friedman; James K Young Journal: Circulation Date: 2007-01-29 Impact factor: 29.690
Authors: Christopher S D Almond; Ravi R Thiagarajan; Gary E Piercey; Kimberlee Gauvreau; Elizabeth D Blume; Heather J Bastardi; Francis Fynn-Thompson; T P Singh Journal: Circulation Date: 2009-01-26 Impact factor: 29.690
Authors: Anne I Dipchand; David C Naftel; Brian Feingold; Robert Spicer; Delphine Yung; Beth Kaufman; James K Kirklin; Tina Allain-Rooney; Daphne Hsu Journal: J Heart Lung Transplant Date: 2009-09-26 Impact factor: 10.247
Authors: Björn Zethelius; Lars Berglund; Johan Sundström; Erik Ingelsson; Samar Basu; Anders Larsson; Per Venge; Johan Arnlöv Journal: N Engl J Med Date: 2008-05-15 Impact factor: 91.245
Authors: Robert E Shaddy; Mark M Boucek; Daphne T Hsu; Robert J Boucek; Charles E Canter; Lynn Mahony; Robert D Ross; Elfriede Pahl; Elizabeth D Blume; Debra A Dodd; David N Rosenthal; Jeri Burr; Bernie LaSalle; Richard Holubkov; Mary Ann Lukas; Lloyd Y Tani Journal: JAMA Date: 2007-09-12 Impact factor: 56.272
Authors: Steven E Lipshultz; Thomas R Cochran; David A Briston; Stefanie R Brown; Peter J Sambatakos; Tracie L Miller; Adriana A Carrillo; Liat Corcia; Janine E Sanchez; Melissa B Diamond; Michael Freundlich; Danielle Harake; Tamara Gayle; William G Harmon; Paolo G Rusconi; Satinder K Sandhu; James D Wilkinson Journal: Future Cardiol Date: 2013-11
Authors: Steven E Lipshultz; Jayanthi J Chandar; Paolo G Rusconi; Alessia Fornoni; Carolyn L Abitbol; George W Burke; Gaston E Zilleruelo; Si M Pham; Elena E Perez; Ruchika Karnik; Juanita A Hunter; Danielle D Dauphin; James D Wilkinson Journal: Clinics (Sao Paulo) Date: 2014 Impact factor: 2.365